Physician profile
Ashish Verma
NPI 1649238213
$179,402.53
in general payments reported to CMS, 2019-2025
51 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $22K · 2021: $41K · 2022: $41K · 2023: $14K · 2024: $6,047 · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $7,101 · Travel and Lodging: $6,839 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,893.75 |
| Food and Beverage | $7,100.85 |
| Travel and Lodging | $6,839.44 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $115,070.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $49,776.94 | 2019-2025 | |
| Verity Pharmaceuticals INC. | $4,792.34 | 2025 | Tlando |
| Medtronic, INC. | $1,417.02 | 2021-2025 | Minimed 780g, Accurian, Axium Primetm |
| Abbott Laboratories | $1,088.75 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $1,069.95 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $615.43 | 2020-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.54 | 2019-2024 | Jardiance, Synjardy |
| Corcept Therapeutics | $452.80 | 2021-2025 | Korlym |
| Abbvie INC. | $384.43 | 2019-2025 | Synthroid |
| Dexcom, INC. | $373.38 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $338.50 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $329.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $289.87 | 2019-2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $246.13 | 2019-2025 | Unithroid |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $208.45 | 2019-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $203.31 | 2025 | Yorvipath |
| Becton, Dickinson and Company | $192.04 | 2019-2022 | |
| Nevro Corp. | $189.25 | 2022-2023 | Senza |
| Sequel Med Tech, LLC | $184.30 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $177.89 | 2021-2025 | Isturisa, Signifor Lar |
| Amryt Pharma Holdings Ltd | $168.13 | 2022-2023 | Mycapssa |
| Mannkind Corporation | $157.69 | 2019-2024 | Afrezza |
| Medtronic Minimed, INC. | $116.31 | 2019-2020 | |
| Ibsa Pharma INC. | $108.35 | 2019-2025 | Tirosint, Licart, Tirosint |
| Antares Pharma, INC. | $87.75 | 2024-2025 | Xyosted, Tlando |
| Ipsen Biopharmaceuticals, INC | $84.93 | 2021-2022 | |
| Halozyme INC | $79.66 | 2023 | |
| Amarin Pharma, INC. | $78.00 | 2020-2021 | |
| Radius Health, INC. | $71.15 | 2021-2023 | Tymlos |
| Tandem Diabetes Care, INC. | $61.40 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Chiesi USA, INC. | $53.21 | 2024 | Mycapssa, Myalept |
| Beta Bionics, INC. | $47.62 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Neurocrine Biosciences, INC. | $46.89 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.12 | 2019-2024 | Xifaxan |
| Embecta Corp. | $35.44 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Tolmar, INC. | $32.13 | 2024-2025 | Jatenzo |
| Acella Pharmaceuticals, LLC | $31.70 | 2025 | NP Thyroid 60 |
| Rgh Enterprises LLC | $27.00 | 2025 | |
| Eusa Pharma (US) LLC | $26.41 | 2022 | |
| Zealand Pharma US, INC. | $23.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.23 | 2021 | |
| Madrigal Pharmaceuticals | $19.94 | 2025 | Rezdiffra |
| Alvogen INC | $18.98 | 2025 | Teriparatide |
| Horizon Therapeutics Plc | $18.35 | 2023 | Tepezza |
| Biohaven Pharmaceuticals, INC. | $17.67 | 2021 | |
| Currax Pharmaceuticals LLC | $13.78 | 2021 | |
| Vifor Pharma, INC. | $13.70 | 2021 | |
| Lifescan, INC. | $12.52 | 2022 | |
| Cequr Corporation | $10.28 | 2021 | |
| Theracosbio, LLC | $9.69 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.